Resistance of non-small cell lung cancer (NSCLC) to EGFR tyrosine kinase inhibitors (TKIs) limits the efficacy and leads to disease progression with mechanisms such as activation of autophagy in tumor cells, but the current therapeutic strategies are unable to... ...

请注册登录后继续浏览